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Abstract
Background: Healthcare resource utilization in breast cancer varies by disease characteristics and treatment
choices. However, lack of clarity in guidelines can result in varied interpretation and heterogeneous treatment
management and costs. In Europe, the extent of this variability is unclear. Therefore, evaluation of chemotherapy
use and costs versus hormone therapy across Europe is needed.
Methods: This retrospective chart review (N = 355) examined primarily direct costs for chemotherapy versus
hormone therapy in postmenopausal women with hormone-receptor–positive (HR+), human epidermal growth
factor receptor-2–negative (HER2–) advanced breast cancer across 5 European countries (France, Germany, The
Netherlands, Belgium, and Sweden).
Results: Total direct costs across the first 3 treatment lines were approximately €10 000 to €14 000 lower for an
additional line of hormone therapy-based treatment versus switching to chemotherapy-based treatment. Direct
cost difference between chemotherapy-based and hormone therapy-based regimens was approximately €1900 to
€2500 per month. Chemotherapy-based regimens were associated with increased resource utilization (managing
side effects; concomitant targeted therapy use; and increased frequencies of hospitalizations, provider visits,
and monitoring tests). The proportion of patients taking sick leave doubled after switching from hormone
therapy to chemotherapy.
Conclusions: These results suggest chemotherapy is associated with increased direct costs and potentially with
increased indirect costs (lower productivity of working patients) versus hormone therapy in HR+, HER2– advanced
breast cancer.
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Background
Breast cancer is one of the most commonly diagnosed
cancers in women, with an estimated 463 819 new cases
diagnosed in Europe in 2012 [1]. The economic burden
of this disease is also high; across the European Union,
breast cancer generated the highest estimated healthcare
costs (6 billion Euros/year) and accounted for 13 % of the
total healthcare costs for cancer [2, 3]. However, health-
care resource utilization in breast cancer varies by disease
stage and treatment choice [4]. In advanced breast cancer
(ABC), hormone therapy and chemotherapy are treatment
options that have (to some extent) guideline-specific
recommendations regarding initiation of use [5–10].
Hormone therapy is recommended as adjuvant therapy
and is viewed as standard of care for hormone-receptor–
positive (HR+) ABC [6–9]. The value of adjuvant chemo-
therapy in this setting is unclear [11], and most guidelines
recommend sequential endocrine therapies except in pa-
tients with proof of hormone resistance or symptomatic
visceral disease [8, 9, 12]. However, guidelines for the se-
quence and preferred number of hormone therapy lines
that can be used before switching to chemotherapy in
ABC—outside of medical necessity—are not always clear
[8, 9, 12]. This lack of clarity can result in varied interpret-
ation of guidelines and can lead to heterogeneous treat-
ment management and costs.
Use of chemotherapy in HR+ ABC is associated with ex-
tensive healthcare costs in the United States (US) [13–16];
evaluations of chemotherapy costs for HR+ ABC in Eur-
ope have not been reported. For example, a US study of
1266 women with HR+ ABC reported that treatment costs
for the year following initiation of chemotherapy were
$32 083 higher than the 1-year treatment costs before
chemotherapy [14]. Furthermore, a recent evaluation of
total direct costs in the US for treating ABC reported that
the monthly per-patient direct cost was lowest with sys-
temic hormone therapy ($5303) compared with chemo-
therapy ($13 261) [13]. The cost of chemotherapy in the
US can be primarily attributed to costs other than the
drug itself (25 % drug cost and 75 % nondrug costs such
as infusion administration and hospitalizations or emer-
gency room visits related to drug) [16]. Because European
treatment patterns may vary from those in the US, similar
evaluation of chemotherapy use and costs versus hormone
therapy across Europe is needed.
This chart review evaluates the resource utilization
and direct cost implications of chemotherapy versus
hormone therapy based on actual physician-reported
treatments from adjuvant therapy to completion of 3 or
more lines of therapy in the advanced setting in post-
menopausal women diagnosed with HR+, human epider-
mal growth factor receptor-2–negative (HER2−) ABC
from 2008 through 2012 in France, Germany, The
Netherlands, Belgium, and Sweden.
Methods
Study design
This retrospective chart review was conducted from
April to June 2012 by physicians or healthcare providers
(HCPs) in the areas of gynecology and medical or clinical
oncology who treat ABC. The participating medical pro-
fessionals were recruited from across France, Germany,
The Netherlands, Belgium, and Sweden to complete a
questionnaire based on their patient charts. Selection of
the medical professionals was based on years of clinical
practice postresidency or postfellowship (≥5 but ≤35 years),
time spent treating patients (≥60 %), and the number
of patients with breast cancer for whom they were re-
sponsible for systemic treatment decisions in the year
preceding the study (≥50 but ≤1000 patients). Medical
professionals were contacted via email to assess their
interest in participation (based on a database of breast
cancer oncologists and record of previous participation in
such research), and a follow-up phone call was made to
discuss details of the research when requested by the
potential participant. All participating physicians electron-
ically signed a consent form before entering data. Data
collected in the questionnaire were from anonymous pa-
tient charts, and the study was compliant with both Euro-
pean and individual country regulations. Ethics approval
was deemed not applicable for this study because it was
done under market research regulations through a phys-
ician panel (fully double blinded physician list) and only
collected fully anonymous patient chart information with-
out any patient identifiers or ability to follow-up with phy-
sicians. Online patient record forms did not collect any
data that would (or could reasonably) lead to the patient
being identified (no name, address, postal code, date of
birth, etc.). No patient or physician identifier is recorded
in the database, and only aggregated data were shared
with the sponsor. The survey methodology was compliant
with guidelines from a number of market research and
pharma associations. A list of authorities this survey
methodology was compliant with at the time of survey ad-
ministration is available in Additional file 1: Table S1.
The study objective was to understand the treatment
patterns and quantify resource utilization of HR+, HER2
− ABC, with the overall aim of describing the costs as
patients progress in the ABC setting.
Chart inclusion criteria
The key inclusion criteria for charts reviewed were post-
menopausal women with HR+, HER2− ABC, defined as
metastatic or locally advanced breast cancer not amen-
able to curative treatment by surgery or radiotherapy;
living or deceased patients with recurring or de novo
diagnosis were eligible, and the diagnosis of ABC had
to be made in 2008 through 2012. For a chart to be
eligible, the patients had to have progressed on at
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least 1 hormone therapy line in the adjuvant or advanced
disease setting (could be administered with chemotherapy
or targeted therapy) and had to have completed at least 1
chemotherapy line (minimum 2 cycles) in the ABC setting
after hormone therapy.
Data collection
Data collected in the questionnaire included patient
demographics and disease state and characteristics at the
initiation of each treatment line, together with informa-
tion on any/all metastases, and all comorbidities (please
see Additional file 2: Figure S1 for a copy of the full
questionnaire). Maintenance therapy was considered a
separate treatment line. Treatment details were re-
quested at each line, including agent dose, duration, and
administration route. Data were also collected on patient
performance status and side effects of chemotherapy
and any complementary treatments to alleviate those
Table 1 Unit cost data by country in Euros
Francea Germanya Netherlandsa Belgiuma Swedena
Healthcare Provider Visit
Oncologist 45.00 50.65 72.00 54.98 126.47
General practitioner 23.00 35.75 28.00 23.67 73.03
Physiotherapist 30.00 20.00 35.00 25.00 36.63
Dietician 61.07 20.00 27.00 30.00 50.00
Psychotherapist 37.00 33.30 77.00 50.00 100.00
Outpatient (ambulatory care) 150.00 157.61 150.00 120.00 285.93
Day-care hospitalization 295.51 200.00 251.00 350.00 529.43
Home nurse visits 40.00 36.16 35.00 40.00 68.03
Palliative care (outpatient) 40.00 36.16 35.00 40.00 68.03
Hospitalization (inpatient) 3204.00 3317.61 2931.18 2534.00 4007.79
Palliative care (inpatient) 6346.00b 1339.98c 3057.17d 3500.00b 5981.83b
Diagnostic/Monitoring Test
CBC 8.37 9.10 8.74 8.15 8.74
Blood chemistry panel 38.37 39.95 32.00 32.62 41.74
Blood tumor markers 16.70 8.70 9.00 25.00 20.74
Creatinine (urine) 2.07 1.80 2.07 1.75 1.74
Hematuria (urine) 2.35 1.25 2.35 1.75 1.74
Bicarbonates (urine) 2.35 1.25 2.35 1.75 1.74
Mammography 66.42 62.96 83.48 41.89 77.65
Bone X-ray 47.88 87.97 106.63 60.00 70.71
Chest X-ray 42.56 50.00 77.74 50.08 89.00
DXA 39.96 30.90 31.50 47.00 57.96
PET-CT 1034.00 1100.00 1454.80 1000.00 1390.80
CT scan 313.10 225.71 218.04 200.00 298.44
MRI 365.11 558.28 377.29 250.00 700.00
Bone scintigraphy 180.44 226.20 189.19 200.00 250.00
Liver ultrasound 56.70 61.58 38.20 ND 123.29
Primary tumor biopsy 176.80 193.93 205.97 261.41 274.57
Metastases biopsy 176.80 193.93 205.97 261.41 274.57
Electrocardiogram 13.52 19.80 39.40 19.80 22.26
Abbreviations: CBC complete blood count, CT computed tomography, DXA dual-energy x-ray absorptiometry, MRI magnetic resonance imaging, ND no data,
PET-CT positron emission tomography–computed tomography




dMean stay, 8 days
Jerusalem et al. BMC Cancer  (2015) 15:787 Page 3 of 12
effects. Reasons for switching to the next line of treat-
ment were also collected. The information collected on
resource utilization at each treatment line included
number of physician visits (office and outpatient), hospi-
talizations (by diagnosis-related group codes, where
available) and duration of stay, any additional treatments
or HCP visits, disease monitoring information (type, fre-
quency, location, and medical professional responsible),
and working status.
Statistical analysis
Information from the questionnaires was summarized by
line of therapy. As a result, the charts were divided into
3 cohorts by key treatment algorithms based on se-
quence of hormone therapy and chemotherapy. Follow-
ing adjuvant therapy, hormone therapy-sensitive disease
was defined as relapsed >1 year after adjuvant therapy
and hormone therapy-refractory disease as relapsed
during adjuvant therapy or within 1 year after adjuvant
therapy. A subgroup analysis of patients eligible for hor-
mone therapy at second line was defined by response to
hormone therapy of ≥6 months in the previous line of
therapy, no significant metastasis progression, and/or no
visceral crisis or brain metastases. Direct and indirect
costs due to treatments were summarized by descriptive
statistics. The unit costs by month and by treatment line
for drugs, monitoring, hospitalizations, HCP visits, and
palliative care were calculated for each patient chart
based on the cost assumptions for each country from
2012 in Euros (Table 1). No adjustments for inflation
were made, as the charts included were from a relatively
short 4-year time span (2008–2012) during which the in-
flation rate in the European Union was ~8.1 %, which is
not considered to be a significant enough change to im-
pact the resource utilization frequency/distribution [17].
The sums of each unit cost for all patient charts in each
cohort were then averaged. Costs were not analyzed per
country because of low patient numbers. The Web-based
Mann-Whitney U test [18] (Wilcoxon rank-sum test) was
used for group cost comparisons, with 2-sided p values.
Analyses were performed using Microsoft Excel.
Results
Physician base
Ninety-four physicians contributed 399 eligible patient
charts (Table 2). There were similar numbers of physi-
cians from each of the 5 European countries; however,
physicians from France contributed ~25 % of the total
number of charts. The majority of physicians reported a
medical oncology specialty (62 %), whereas 23 % re-
ported clinical oncology and 15 % reported gynecology
(in some countries gynecologists treat patients with
ABC) as their speciality. The majority of physicians re-
ported that they treat patients at a teaching hospital
(47 %) or general hospital (32 %), and 63 % of physicians
treated 50 to 200 patients in the year preceding the study.
Patient base
Treatment patterns allowed the division of 355 patients
with ABC into 3 cohorts: cohort A (hormone therapy
first line, chemotherapy second line, and any treatment
third line), cohort B (hormone therapy first and second
lines, and chemotherapy third line), and cohort C
(chemotherapy first line, and any treatment second and
third lines) (Fig. 1, Table 3). In general, patient demo-
graphics and disease characteristics were similar across
the 3 cohorts (Table 4). However, patients in cohort C
were more likely to have a family history of breast and/or
ovarian cancer and to present with liver and brain
metastases at ABC diagnosis. The remaining 44 patient
charts were excluded from the analysis because they did
not meet the criteria for these 3 cohorts: 36 patients
received only 1 therapy line in ABC and 8 patients
received hormone therapy for 3 lines of treatment before
switching to chemotherapy.
The majority of patient charts (62 %) fit the treatment
pattern for cohort A, and in this cohort the largest
percentage of patients was diagnosed with de novo
ABC (46 %). Approximately 50 % of these patients
were diagnosed with hormone-sensitive recurrent dis-
ease. Cohort C consisted of 31 % of the patient
charts. Patients in this cohort were primarily diagnosed
with recurrent disease and were evenly split between
hormone-refractory and hormone-sensitive. Cohort B was
excluded from further analyses because of the low patient
numbers (n = 26).
The majority of patients in each cohort received adju-
vant treatment: 47 % in cohort A and 77 % in cohort C.
Overall, hormone therapy was the most common adjuvant
therapy across cohorts (79 % and 93 %, respectively).
However, chemotherapy use and targeted therapy use
were higher in cohort C (81 % and 15 %, respectively)
compared with cohort A (56 % and 5 %, respectively).
A small group of patients in each cohort received
anti-HER2 therapy (ie, lapatinib or trastuzumab) des-
pite being recorded as having HR+, HER2− disease.
Table 2 Evidence base for chart review
Country Charts, n Participating
physicians, n
Gynecologists, %a
France 105 21 —
Germany 79 21 48
The Netherlands 68 19 —
Belgium (Flemish region) 84 17 24
Sweden 63 16 —
TOTAL 399 94 15
aPercentage of participating physicians who were gynecologists
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Anti-HER2 therapy was prescribed for 13 patients (23
prescriptions) in cohort A and 17 patients (21 pre-
scriptions) in cohort B. These anti-HER2 prescriptions
accounted for approximately 10 % of the overall treat-
ment costs reported here.
Direct costs
The overall cost differences between hormone therapy
and chemotherapy across all 3 cohorts combined indi-
cates that hormone therapy in the first or first and sec-
ond line is associated with lower costs compared with
Fig. 1 Flow diagram showing the methodology for comparison of resource utilization in the three cohorts. Abbreviations: ABC, advanced breast
cancer; HT, hormone therapy; TT, targeted therapy
Table 3 Patient cohorts recorded in the chart review
Cohort A (n = 218) HT 1st line,
CT 2nd line, Any Trx 3rd line
Cohort B (n = 26) HT 1st line,
HT 2nd line, CT 3rd line
Cohort C (n = 111) CT 1st line,
Any Trx 2nd line Any Trx 3rd line
Average duration of 3 therapy lines, months 20.9 22.9 19.7
Breast cancer history at ABC diagnosis, n (%)
Recurring during adjuvant therapy 37 (17) 3 (12) 30 (27)
Recurring ≤1 year after adjuvant therapy 14 (6) 2 (8) 21 (19)
Recurring >1 year after adjuvant therapy 66 (30) 13 (50) 38 (34)
De novo ABC 101 (46) 8 (31) 22 (20)
Adjuvant drug therapies, n (%)
Any 102 (47) 17 (65) 86 (77)
None 116 (53) 9 (35) 25 (23)
First-line ABC setting, n (%)
Hormone therapy 218 (100) 26 (100) 32 (29)
Chemotherapy 0 0 111 (100)
Targeted therapy 7 (3) 0 24 (22)
Second-line ABC setting, n (%)
Hormone therapy 18 (8) 26 (100) 59 (53)
Chemotherapy 218 (100) 0 65 (59)
Targeted therapy 45 (21) 1 (4) 13 (12)
Third-line ABC setting, n (%)
Hormone therapy 31 (14) 1 (4) 12 (11)
Chemotherapy 39 (18) 26 (100) 31 (28)
Targeted therapy 10 (5) 2 (8) 9 (8)
None 149 (68) 0 73 (66)
Abbreviation: ABC advanced breast cancer, CT chemotherapy, HT hormone therapy, Trx treatment
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chemotherapy in the same treatment settings (Table 5).
Furthermore, substantial direct cost differences were
identified for patients whose disease progressed during
or within 1 year of adjuvant hormone therapy (hormone
therapy-refractory) as well as for patients whose disease
progressed more than 1 year after adjuvant endocrine
therapy or who presented with de novo advanced breast
cancer (hormone therapy-eligible).
Over all 3 treatment lines, total direct costs were sig-
nificantly lower in cohort A, which received hormone
therapy first line, compared with cohort C (p < 0.001,
Mann-Whitney U test), which received chemotherapy
first line (Fig. 2). Chemotherapy as first-line treatment
(cohort C) increased overall costs by €14 362 compared
with first-line hormone therapy (cohort A), despite lon-
ger average duration of overall treatment in cohort A
versus cohort C (20.9 vs 19.7 months, respectively). A
subgroup analysis of patients who were eligible for hor-
mone therapy as second-line treatment (n = 248) showed
that use of chemotherapy as second-line treatment in-
stead of hormone therapy increased overall costs by €10
302. Because duration of treatment varied across lines
and types of therapy within each cohort, monthly direct
costs were also examined, and they were found to have
Table 4 Patient demographics and disease characteristics
Cohort A (n = 218) Cohort B (n = 26) Cohort C (n = 111) Overall (n = 355)
Median age, years 64 61 61 63
Family history, breast/ovarian cancer, n (%) 35 (16) 3 (12) 29 (26) 67 (19)
ECOG performance status, n (%)
0–1 168 (77) 26 (100) 94 (85) 288 (81)
2–4 44 (20) 0 17 (15) 61 (17)
Missing 6 (3) 0 0 6 (2)
AJCC stage grouping, n (%)
IIIA 41 (19) 4 (15) 16 (14) 61 (17)
IV 146 (67) 22 (85) 70 (63) 238 (67)
PgR-positive status, n (%)a 155 (71) 19 (73) 69 (62) 243 (68)
Tumor proliferation, n (%)a
Ki-67 status <20 % 26 (12) 2 (8) 20 (18) 48 (14)
Grade 3 100 (46) 11 (42) 53 (48) 164 (46)
Metastatic site, n (%)
Brain 6 (3) 0 13 (12) 19 (5)
Lung 72 (33) 6 (23) 36 (32) 114 (32)
Liver 61 (28) 3 (12) 52 (47) 116 (33)
Bone 118 (54) 22 (85) 60 (54) 200 (56)
Abbreviations: AJCC American Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, PgR progesterone receptor
aMay reflect baseline characteristics before advanced breast cancer (ABC) diagnosis when biopsy was not conducted at ABC diagnosis
Table 5 Cost differences between chemotherapy-based and hormone therapy-based therapy options based on hormone therapy
sensitivitya
Total Cohort Analysis Subgroup analysis
Patient group description All patients (n = 355) HT-refractoryb in 1st line
(n= 107)
HT-eligiblec in 2nd line
(n= 248)
Total cost difference (over 3 lines of therapy)d HT instead of CTx in 1st line €14 362 €7300 NA
HT instead of CTx in 2nd line €10 368 NA €10 300
Cost difference (for 1 line of therapy)d 1st line HT vs 2nd line CTx €9879 (~€1900/mo) €7550 (~€1650/mo) NA
1st line HT vs 1st line CTx €15 167 (~€2500/mo) €13 850 (~€2350/mo) NA
2nd line HT vs 2nd line CTx €8201 (~€1700/mo) NA €8550 (~€1700/mo)
Abbreviations: ABC advanced breast cancer, CTx chemotherapy, HT hormone therapy, mo month, NA not applicable
aNumbers in the table reflect cost savings with HT versus CTx
bHormone refractory indicated recurrence within 1 year of adjuvant HT
cHormone eligible indicates de novo (no adjuvant therapy) or recurrent disease ≥1 year following adjuvant HT
dCosts analysis was based on unit cost assumptions for each country, which were then averaged
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the same pattern as overall costs. In first-line therapy,
the monthly direct costs for chemotherapy were €2536
higher versus hormone therapy (p < 0.001, Mann-Whitney
U test) (Fig. 3). In second-line therapy, the monthly direct
costs for chemotherapy were €1891 higher compared with
hormone therapy in the first line (p < 0.001, Mann-
Whitney U test). A subgroup analysis of patients who
were eligible for hormone therapy as second-line treat-
ment showed that use of chemotherapy as second-line
treatment instead of hormone therapy increased monthly
costs by a similar amount (€1705).
Drivers of increased direct costs for chemotherapy
Most of the increased cost for chemotherapy was due to
the drug cost itself (Table 6), and there was increased
use of other therapies with chemotherapy. Compared
with first-line hormone therapy (cohort A), first-line
chemotherapy (cohort C) was associated with approxi-
mately 7-fold increased use of concomitant targeted
therapies and with increased use of complementary
treatments to manage chemotherapy side effects (Fig. 4).
Bevacizumab was the most commonly used targeted
therapy, followed by trastuzumab and lapatinib. Increased
resource utilization resulted in approximately double
the resource costs for chemotherapy compared with
hormone therapy (Table 6). Moreover, the analysis of
healthcare resource utilization in cohort A showed
that second-line chemotherapy was associated with
increased frequencies of hospitalizations, ambulatory
care and HCP visits, and a subset of monitoring tests
compared with first-line hormone therapy (Fig. 5). A
similar trend was observed for chemotherapy in the
other cohorts (data not shown).
Indirect costs
Indirect cost increases were attributed to the lower
productivity of working patients: at ABC diagnosis 43 %
of patients in cohort A and 56 % of patients in cohort C
were working full or part time. In cohort A, there was a
greater increase in sick leave during chemotherapy use
compared with hormone therapy, which lowered the
productivity of working-age patients and would result in
indirect cost increases (Table 7). This increase in sick
leave during chemotherapy versus hormone therapy was
also observed across cohorts during the same line of
treatment, with a notable increase during second-line
treatment for cohort A (41 % for chemotherapy) com-
pared with first-line treatment (19 % for hormone ther-
apy). Additionally, in cohort A the increase in sick leave
was accompanied by a substantial corresponding decrease
in the proportion of patients working during second-line
treatment (10 % for chemotherapy) compared with first-
line treatment (32 % for hormone therapy). In contrast,
only a small decrease in the proportion of working
Fig. 2 Direct overall costs by patient cohort. The costs in cohort A were significantly lower than the costs in cohort C (p < 0.001, Mann-Whitney U test).
Average treatment durations by type and line of therapy in each cohort are shown in parentheses. Abbreviations: HT, hormone therapy;
Tx, treatment; wk, week(s)
Fig. 3 Direct average monthly costs by patient cohort and line of
treatment. Costs in cohort A 1st line (HT) were significantly lower
compared with costs in cohort A 2nd line (chemotherapy) and cohort
C (any therapy; p < 0.001 for both comparisons, Mann-Whitney U test).
Abbreviation: HT, hormone therapy
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patients was observed between first line chemotherapy
(26 %) and any second line therapy (22 %) in Cohort C.
Overall, the working categories of retired (normal and
early) and unemployed remained relatively stable over the
course of the 3 treatments in both cohorts.
Discussion
Several treatment options are provided by international
guidelines for European patients with ABC at each point
in disease progression. However, physicians in individual
countries may have limited treatment choices that are
guided by country-specific restrictions, separate guide-
lines, or required procedures. Furthermore, specific guid-
ance may be influenced by a country’s healthcare resources
and/or benefit-to-cost ratios. The present study used recent
patient records to examine uses of healthcare resources
and their associated costs across 5 European countries in
the ABC setting. The results demonstrated that total direct
costs over the first 3 lines of therapy for HR+, HER2− ABC
in postmenopausal women were €10 000 to €14 000 lower
if a hormone therapy-based regimen was used for 1 add-
itional line of therapy versus switching to chemotherapy.
The increase in direct costs for chemotherapy versus hor-
mone therapy was also found in first-line and second-line
treatments individually. Moreover, chemotherapy costs
were increased despite longer duration of therapy in
the cohort receiving hormone therapy.
The results of this study are supported by a study that
found increased treatment costs associated with chemo-
therapy compared with hormone therapy in the ABC
setting. A recent evaluation of total direct costs in the
US for treating ABC reported that the monthly per-patient
direct cost was lowest with systemic hormone therapy
($5303; n = 3187) compared with HER2-targeted therapy
($10 083; n = 711) or chemotherapy ($13 261; n = 2278)
and was highest with no systemic therapy at all ($13 926;
Table 6 Costs contributing to monthly direct cost for chemotherapy-based and hormone therapy-based treatment
Average monthly costs (median monthly costs) and contribution percentagesa
Contributor Hormone therapy 1st line,
Cohort A (n = 218)
Chemotherapy 1st line,
Cohort C (n = 111)
Chemotherapy 2nd line,
Cohort A (n = 218)
Drugb Hormone therapy €159 35.5 % €57 1.9 % €23 1.0 %
(€78) (€0) (€0)
Chemotherapy NA NA €1145 38.4 % €873 37.3 %
(€942) (€515)
Targeted therapy €72 16.1 % €897 30.1 % €863 36.9 %
(€0) (€0) (€0)
Chemotherapy complementary treatment NA NA €325 10.9 % €135 5.8 %
(€0) (€0)
Total €231 51.6 % €2424 81.2 % €1894 81.0 %
Resource Diagnostic/monitoring €135 30.2 % €298 10.0 % €212 9.1 %
(€114) (€225) (€157)
Hospitalizationc €12 2.6 % €75 2.5 % €54 2.3 %
(€0) (€0) (€0)
Physician visitsd €64 14.4 % €163 5.5 % €155 6.6 %
(€19) (€113) (€109)
Other HCP visitse €5 1.0 % €15 0.5 % €7 0.3 %
(€0) (€5) (€3)
Palliative caref €0.3 0.1 % €10 0.3 % €15 0.6 %
(€0) (€0) (€0)
Total €216.3 48.4 % €561 18.8 % €443 19.0 %
Average monthly cost €447 €2983 €2338
Abbreviations: HCP healthcare professional, NA not applicable
aCosts and percentages are rounded to the nearest Euro (where possible) and 10th place, respectively, which may lead to slight differences in some totals. Note
that median costs may be markedly different from the average costs. For example, if a large number of patients in a group had no hospitalizations while a small
number of patients in the group had hospitalizations, the median costs may be zero even though the average costs are high
bIncludes drug cost only to avoid double-counting; administration costs are included in the medical costs below under the assumption that all outpatient visits are recorded
cIncludes daycare inpatient treatments (e.g., drug administration or monitoring) and longer hospitalization
dOncology consultant office, general practitioner, ambulatory care, and nurse home visit
ePhysiotherapist, dietician, and psychotherapist visits
fIncludes daycare and hospitalization for palliative care
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n = 1522) [13]. Until the present study, similar studies in
Europe had not been performed.
Potential cost improvements may have been lost for
patients who were eligible for and could have received
benefit from hormone therapy in second line but who
instead received chemotherapy. Accordingly, this study
further examined the possible reasons for the increased
cost associated with chemotherapy-based regimens. There
were increased healthcare resource utilization costs for
monitoring events, complementary therapies to manage
side effects, and physician visits with chemotherapy-based
regimens compared with hormone therapy. These findings
are supported by a US study of 1444 women receiving
chemotherapy for ABC, wherein healthcare resources
other than the cost of chemotherapy comprised >50 % of
the total costs: outpatient services accounted for 29 % of
the total cost and medications other than chemotherapy
accounted for 26 % [19]. In addition, patients receiving
chemotherapy also had greater targeted therapy use com-
pared with patients receiving hormone therapy in our
study. Globally, the general use of targeted therapies will
most likely increase as more of these agents are shown to
provide clinical benefit and are approved. In the future,
targeted therapies may also be used increasingly in com-
bination with hormone therapy. Consequently, the total
costs for hormone therapy-based therapy will increase.
However, combinations with targeted agents may allow
the extended use of lower-cost hormone therapy in pa-
tients who may derive clinical benefit, allowing a delay in
switching to cytotoxic chemotherapy. In this study, the
group of patients receiving targeted therapy in combin-
ation with hormone therapy was too small to be evaluated.
We anticipate that a more in-depth review of these costs
will become feasible in the future.
Another increased cost associated with chemotherapy-
based versus hormone therapy-based regimens was
indirect cost from lower work productivity, with a 3-fold
lower proportion of patients working during second-line
chemotherapy compared with hormone therapy. Overall,
indirect costs associated with work status vary according
to age. For example, a Swedish study stratified the total
cost of all breast cancer cases in 2002 and reported higher
indirect costs in breast cancer from sick leave, early retire-
ment, and premature mortality (70 % of total) compared
with direct costs [20]. However, the primary reason indir-
ect costs dominated the total cost was because most of
these breast cancer cases were in patients <65 years of age
who were still in the workforce. Patients in the present
study had a median age of 63 years; therefore, in theory,
the working population accounted for ~50 % of the study’s
total population, which would lessen the effect of indirect
costs. A US study modeling the total costs specifically for
ABC over 5 years (based on data from 2007) reported that
lost work productivity accounted for only 21 % of the total
cost for ABC [21]. The present study is the first to report
a detailed assessment of work status over time stratified
by treatment regimen in the ABC setting.
Limitations of this study are those primarily inherent
to chart reviews. As with any chart review, there are lim-
itations to the information available retrospectively that
Fig. 4 Overall use of concomitant targeted therapies and complementary treatments to manage chemotherapy side effects. Abbreviations: HT,
hormone therapy; Rx, prescriptions; TT, targeted therapy. *Data presented for first line of chemotherapy treatment in each cohort
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could have affected treatment decisions, such as accurate
assessment of HER2 status. Although the inclusion cri-
teria stated HER2− disease, trastuzumab and lapatinib
were used in a small percentage of patients. It is unclear
whether these patients had confirmed HER2− disease
and HER2-targeted therapies were used because there
were limited treatment options, the patients had uncon-
firmed HER2− disease and HER2-targeted therapies were
used as general practice, or the patients had participated
in a past trial of HER2-targeted therapy that did not re-
quire documented HER2+ status at study entry. In some
cases, the anti-HER2 therapy might have been used
when the metastatic site was not able to be biopsied
with the expectation that the tumor characteristics
might have changed. Additionally, physicians may have
based the treatment on results from the EGF30008 trial
of lapatinib in combination with endocrine therapy [22].
In addition, accurate detailed information on the
therapeutic regimens may be limited. These concerns
were somewhat mitigated by having the treating phys-
ician complete the questionnaire using relatively recent
patient charts. However, information that the treating
physician may not be familiar with may be limiting, such
as an accurate number of HCP visits for drug adminis-
tration that can result in underestimation of utilization
costs. In addition, HCP visits could have been underre-
ported. In that case, HCP visit costs could be higher
than the reported costs for the lines of therapy and
cohorts wherein chemotherapy was used.
Another limitation to this study is the assumption that
unit costs were the same within each country. Costs
were calculated for each patient based on national costs
in the country of the patient. However, local differences
may exist that would introduce uncertainties into the
difference between chemotherapy and hormone therapy
Table 7 Working statusa during ABC treatment for patients <65 years of age
Patients, n (%)
Full-time work Part-time work Sick leave Retired early
Cohort A
ABC diagnosis (n = 109) 26 (24) 21 (19) 6 (6) 7 (6)
1st-line hormone therapy (n = 109) 13 (12) 22 (20) 21 (19) 8 (7)
2nd-line chemotherapy (n = 109) 2 (2) 9 (8) 45 (41) 10 (9)
3rd-line any therapy (n = 39) 1 (3) 2 (5) 16 (41) 5 (13)
Cohort C
ABC diagnosis (n = 70) 26 (37) 13 (19) 5 (7) 4 (6)
1st-line chemotherapy (n = 70) 6 (9) 12 (17) 29 (41) 4 (6)
2nd-line any therapy (n = 70) 8 (11) 8 (11) 29 (41) 6 (9)
3rd-line any therapy (n = 27) 2 (7) 1 (4) 14 (52) 2 (7)
Abbreviation: ABC advanced breast cancer
aThe percentages of patients do not add to 100 % because the working status categories of voluntary work, unemployed, retired, and unknown did not have
appreciable changes within the cohorts over time and are not presented
Fig. 5 Cohort A: hormone therapy versus chemotherapy regimens for
(a) monitoring tests and (b) healthcare resource utilization. Cohort A
received HT 1st line followed by chemotherapy 2nd line and any
treatment 3rd line. Abbreviations: CT, computed tomography; GP,
general practitioner; HT, hormone therapy; MRI, magnetic resonance
imaging; PET, positron emission tomography; TT, targeted therapy
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costs. This study presents an average cost difference
across the 5 European countries. Furthermore, standard
medical practices are similar across the countries in-
cluded in this study.
Finally, although the chart review covered treatments
received from 2008 to 2012, only 2012 reference costs
were used. However, the inflation rate in the European
Union was ~8.1 % between 2008 and 2012, which is not
considered to be a significant enough change to impact
the resource utilization frequency/distribution [17].
Conclusions
In this first study to evaluate the real-world experience
in treating ABC in Europe, chemotherapy-based regi-
mens appear to be associated with increased total direct
costs compared with hormone therapy-based regimens.
The results of the ongoing OPTIMA study in the United
Kingdom are awaited to further aid in making the deci-
sion to initiate chemotherapy in patients with breast
cancer and will also include a cost analysis [23]. Current
international guidelines for the treatment of ABC recom-
mend hormone therapy as long as patients are eligible
(i.e., responsive and without symptomatic visceral metas-
tases or need for rapid treatment control) [5, 8–10, 12],
and this study supports these guidelines with regard
to healthcare resource utilization, healthcare costs, and
work productivity.
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